Other
Neoplasm by Morphology
CI-CAN-00000002Explore in graph →
Non-malignant13,325 active trials222 approved drugs2,774 evidence items
- NCIt
- C4741
Loading cancer entity…
Loading cancer entity…
Other
CI-CAN-00000002Explore in graph →
Clinical trials
52,671 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04378647 | BREntuximab Vedotin in SEcond LIne Therapy BEfore Transplant(BRESELIBET) | unknown | Phase 2 | 150 | Grupo Español de Linfomas y Transplante Autólogo de Médula ÓseaOTHER | 1 | Feb 26, 2024 | clinicaltrials |
| NCT04492293 | An Efficacy and Safety Study of ICP-192 in Subjects With Bladder Urothelial Cancer | unknown | Phase 2 | 115 | Beijing InnoCare Pharma Tech Co., Ltd.INDUSTRY | 1 | Feb 26, 2024 |
| clinicaltrials |
| NCT05163080 | SurVaxM Plus Adjuvant Temozolomide for Newly Diagnosed Glioblastoma (SURVIVE)(SURVIVE) | unknown | Phase 2 | 247 | MimiVax, LLCINDUSTRY | 1 | Feb 26, 2024 | clinicaltrials |
| NCT05371223 | Combined Nabpaclitaxel Pressurized IntraPeritoneal Aerosol Chemotherapy With Systemic Nabpaclitaxel-Gemcitabine Chemotherapy for Pancreatic Cancer Peritoneal Metastases(Nab-PIPAC) | unknown | Phase 2 | 38 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | Feb 26, 2024 | clinicaltrials |
| NCT06277011 | Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10-19) in the Treatment of Relapsed and/or Refractory CD19-positive B Cell Hematological Malignancies Clinical Research | unknown | Early Phase 1 | 18 | Anhui Provincial HospitalOTHER_GOV | 1 | Feb 26, 2024 | clinicaltrials |
| NCT06277947 | Administration of Hyperthermic Intraperitoneal Chemotherapy in the General Ward(GARD-HIPEC) | unknown | N/A | 92 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Feb 26, 2024 | clinicaltrials |
| NCT06278103 | Correlation Between Expression of Hormonal Receptors, Clinical Data, and Methylation Profile in Meningiomas (MethylRH-M)(MethylRH-M) | unknown | — | 180 | Central Hospital, Nancy, FranceOTHER | 0 | Feb 26, 2024 | clinicaltrials |
| NCT02192619 | National Acute Promyelocytic Leukemia (APL) Observational Study NAPOLEON-Registry of the German AML Intergroup | unknown | — | 500 | Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbHOTHER | 1 | Feb 23, 2024 | clinicaltrials |
| NCT04530006 | Acetyl-Amantadine as a Biomarker in Patients With Glioblastoma | unknown | N/A | 20 | CancerCare ManitobaOTHER | 1 | Feb 23, 2024 | clinicaltrials |
| NCT05346198 | Evaluate CART-BCMA in Patients With Relapsed and/or Refractory Multiple Myeloma | unknown | Phase 1 | 15 | Shanghai Simnova Biotechnology Co.,Ltd.INDUSTRY | 1 | Feb 23, 2024 | clinicaltrials |
| NCT05701735 | Decision Aid for Chemotherapy in Cisplatin-Intolerant Patients With Locally Advanced Cervical Cancer(CECIL) | unknown | N/A | 45 | University of Santo Tomas Hospital, PhilippinesOTHER | 1 | Feb 23, 2024 | clinicaltrials |
| NCT05868083 | The Safety and Efficacy of SNC-109 CAR-T Cells Therapy the Recurrent Glioblastoma | unknown | Phase 1 | 16 | Shanghai Simnova Biotechnology Co.,Ltd.INDUSTRY | 1 | Feb 23, 2024 | clinicaltrials |
| NCT06075849 | Phase I Study to Evaluate Safety and Anti-tumor Activity of PB101, an Anti-angiogenic Immunomodulating Agent | unknown | Phase 1 | 30 | Panolos BioscienceINDUSTRY | 1 | Feb 23, 2024 | clinicaltrials |
| NCT06206902 | F01 in the Treatment of Relapsed/Refractory Non-hodgkin's Lymphoma | unknown | Phase 1 | 55 | Shanghai Simnova Biotechnology Co.,Ltd.INDUSTRY | 1 | Feb 23, 2024 | clinicaltrials |
| NCT05178043 | GT90001 Plus Nivolumab in Patients With Advanced Hepatocellular Carcinoma | unknown | Phase 2 | 5 | Suzhou Kintor Pharmaceutical Inc,INDUSTRY | 1 | Feb 22, 2024 | clinicaltrials |
| NCT06271603 | Evaluation of the Efficiency and Economic Impact of LC-OCT (Line-field Confocal Optical Coherence Tomography) for the Diagnosis and Management of Basal Cell Carcinomas(ECOBASO) | unknown | N/A | 704 | Damae MedicalINDUSTRY | 1 | Feb 22, 2024 | clinicaltrials |
| NCT06273709 | Remote Assessment of OCT Scans for BCC Detection | unknown | — | 120 | Maastricht University Medical CenterOTHER | 0 | Feb 22, 2024 | clinicaltrials |
| NCT04096417 | Pemigatinib for the Treatment of Metastatic or Unresectable Colorectal Cancer Harboring FGFR Alterations | unknown | Phase 2 | 14 | Academic and Community Cancer Research UnitedOTHER | 1 | Feb 21, 2024 | clinicaltrials |
| NCT05591053 | Utility and Usability of ActivSight™ Laser Speckle Imaging in Visualization of Tissue Perfusion and Blood Flow During Esophageal Surgery in Humans | unknown | N/A | 70 | Activ SurgicalINDUSTRY | 1 | Feb 21, 2024 | clinicaltrials |
| NCT05865678 | Musculoskeletal Health in Adult Haematological Cancer Survivors(SKETCh) | unknown | — | 650 | The Christie NHS Foundation TrustOTHER | 1 | Feb 21, 2024 | clinicaltrials |
| NCT05924997 | Adebrelimab, Camrelizumab Plus Apatinib as First-line Therapy in Patients With Advanced Hepatocellular Carcinoma | unknown | Phase 1 / Phase 2 | 52 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Feb 21, 2024 | clinicaltrials |
| NCT05930665 | Study of Cadonilimab Combined With Bevacizumab and Standard Chemotherapy as First Line Therapy in Unresectable Pleural Mesothelioma | unknown | Phase 2 | 38 | Sun Yat-sen UniversityOTHER | 1 | Feb 21, 2024 | clinicaltrials |
| NCT06013111 | An Exploratory Clinical Study Evaluating the Safety and Efficacy of Anti-CEA-CAR-T Cells Injection in Patients With CEA+ Locally Advanced and/or Metastatic Solid Tumors | unknown | Phase 1 | 9 | China Medical University, ChinaOTHER | 1 | Feb 21, 2024 | clinicaltrials |
| NCT01754402 | Bendamustine + Pomalidomide + Dex in R/R Multiple Myeloma | unknown | Phase 1 / Phase 2 | 56 | Cristina GasparettoOTHER | 1 | Feb 20, 2024 | clinicaltrials |
| NCT03500380 | A Study of RC48-ADC Administered Intravenously to Patients With HER2-Positive Metastatic Breast Cancer With or Without Liver Metastases | unknown | Phase 2 / Phase 3 | 301 | RemeGen Co., Ltd.INDUSTRY | 1 | Feb 20, 2024 | clinicaltrials |
| NCT03650933 | A Study Comparing the Efficacy and Safety of G-CHOP Versus R-CHOP in Untreated Diffuse Large B-cell Lymphoma Patients | unknown | Phase 3 | 360 | Nanjing Yoko Biomedical Co., Ltd.INDUSTRY | 1 | Feb 20, 2024 | clinicaltrials |
| NCT05135715 | A Study of RC48-ADC in Advanced Melanoma Subjects With HER2 Variant (Mutation, Amplification, Overexpression) | unknown | Phase 2 | 50 | RemeGen Co., Ltd.INDUSTRY | 1 | Feb 20, 2024 | clinicaltrials |
| NCT05297552 | A Study of RC48-ADC Combined With JS001 For Perioperative Treatment of Muscle-Invasive Bladder Cancer | unknown | Phase 2 | 40 | RemeGen Co., Ltd.INDUSTRY | 1 | Feb 20, 2024 | clinicaltrials |
| NCT05364411 | HYpofractionated, Dose-redistributed RAdiotherapy With Protons and Photons in HNSCC(HYDRA) | unknown | N/A | 100 | Joris B.W. ElbersOTHER | 1 | Feb 20, 2024 | clinicaltrials |
| NCT06066255 | PROPHYLAXIS OF GVH IN ELDERLY PATIENTS RECEIVING HAPLOIDENTICAL ALLOGENIC HEMATOPOIETIC STEM CELL TRASNPLANTATION USE OF A LOW DOSE ANTI-LYMPHOCYTIC SERUM(CASPER) | unknown | Phase 2 | 27 | Institut Paoli-CalmettesOTHER | 0 | Feb 20, 2024 | clinicaltrials |
| NCT06186167 | Amyloidosis Incidence in High-Risk Cardiac Device Patients | unknown | — | 100 | Midwest Heart & Vascular SpecialistsOTHER | 1 | Feb 20, 2024 | clinicaltrials |
| NCT06210334 | HAIC Combine Tislelizumab and Lenvatinib in the Treatment of HCC With Type IV (Vp4) Portal Vein Tumor Thrombus (HAI-TL)(HAI-TL) | unknown | Phase 2 | 54 | Li Xiao WeiOTHER | 1 | Feb 20, 2024 | clinicaltrials |
| NCT06238245 | Combination of ATG-based Conditioning Regimen and PTCy for GVHD Prevention in Allo-HSCT After PD-1 Blockade | unknown | Phase 2 | 22 | Beijing 302 HospitalOTHER | 0 | Feb 20, 2024 | clinicaltrials |
| NCT06251492 | Radiation and Adebrelimab in Prostate Cancer With Imaging-measurable Disease (RAPID) | unknown | Phase 2 | 30 | Fudan UniversityOTHER | 1 | Feb 20, 2024 | clinicaltrials |
| NCT06267170 | A Multicenter, Real-world Study of Adebrelimab in the Treatment of Extensive Stage Small Cell Lung Cancer(SCLC) | unknown | — | 288 | Henan Cancer HospitalOTHER_GOV | 0 | Feb 20, 2024 | clinicaltrials |
| NCT03924466 | Repeatability of 68-GaNOTA-Anti-HER2 VHH1 PET/CT in Breast Carcinoma Patients(VUBAR) | unknown | Phase 2 | 55 | Universitair Ziekenhuis BrusselOTHER | 1 | Feb 16, 2024 | clinicaltrials |
| NCT05817279 | AI-aided Optical Coherence Tomography for the Detection of Basal Cell Carcinoma | unknown | — | 124 | Maastricht University Medical CenterOTHER | 1 | Feb 16, 2024 | clinicaltrials |
| NCT06024629 | cOCT Versus LC-OCT for Diagnosing Basal Cell Carcinoma: a Diagnostic Cohort Study | unknown | — | 197 | Maastricht University Medical CenterOTHER | 1 | Feb 16, 2024 | clinicaltrials |
| NCT06148155 | A Study of [68Ga]Ga-NOTA-RG2 PET Imaging in the Diagnosis of Hepatocellular Carcinoma | unknown | N/A | 20 | Huashan HospitalOTHER | 1 | Feb 16, 2024 | clinicaltrials |
| NCT06148220 | A Study of the Clinical Application of [18F]RCCB6 and [68Ga]Ga-NOTA-RCCB6 PET/CT Imaging in the Diagnosis of CD70-expressing Multiple Tumors | unknown | N/A | 20 | Huashan HospitalOTHER | 1 | Feb 16, 2024 | clinicaltrials |
| NCT06262581 | Neoadjuvant Tisleizumab(BGB-A317) for dMMR/MSI-H Non-late Stage CRC Patients Before Surgery | unknown | Phase 2 | 40 | Sun Yat-sen UniversityOTHER | 1 | Feb 16, 2024 | clinicaltrials |
| NCT05284825 | A Phase II Trial of Intermediate Radiation Dose For Lymphoma | unknown | N/A | 27 | Sunnybrook Health Sciences CentreOTHER | 1 | Feb 15, 2024 | clinicaltrials |
| NCT06261879 | Non-invasive Biomarker Discovery for Pre-cervical or/and Cervical Cancer--ACTN4 and Other Biomarkers in Menstrual Blood | unknown | N/A | 300 | WomenX Biotech LimitedINDUSTRY | 1 | Feb 15, 2024 | clinicaltrials |
| NCT06258096 | LI-TASTE Study: Light for Taste(LI-TASTE) | unknown | N/A | 52 | Academic Centre for Dentistry in AmsterdamOTHER | 0 | Feb 14, 2024 | clinicaltrials |
| NCT06258434 | Liquid Biopsy Based Multiomics Study for Colorectal Cancer Early Screening(COLO-LIMULOID) | unknown | — | 1,000 | Sir Run Run Shaw HospitalOTHER | 1 | Feb 14, 2024 | clinicaltrials |
| NCT02730923 | Hormone Receptor Positive endometrIal Carcinoma Treated by Dual mTORC1/mTORC2 Inhibitor and Anastrozole (VICTORIA)(VICTORIA) | unknown | Phase 1 / Phase 2 | 72 | Centre Leon BerardOTHER | 1 | Feb 13, 2024 | clinicaltrials |
| NCT04246710 | Pancreatic Cancer Molecular Sub-classification Using Endoscopic Ultrasound Tissue Core Biopsy Samples | unknown | — | 160 | Catholic University of the Sacred HeartOTHER | 1 | Feb 13, 2024 | clinicaltrials |
| NCT05248750 | Genetic, Microenvironmental, and Immunological Factors in Unresectable Pancreatic Ductal Adenocarcinoma | unknown | — | 250 | Catholic University of the Sacred HeartOTHER | 1 | Feb 13, 2024 | clinicaltrials |
| NCT05829057 | The IIT Study of Evaluation of P-IL-2 Single Agent and With Anti-PD-1 | unknown | Phase 1 | 10 | Zhejiang UniversityOTHER | 1 | Feb 13, 2024 | clinicaltrials |
Data updated 23 days agoSource updated Feb 26, 2024source: clinicaltrials